Diagnostic flow cytometry for low-grade myelodysplastic syndromes

Hematological Oncology

Volumn 26, Issue 4, 2008, Pages 193-198

  Ogata, Kiyoyuki ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

CD34; Diagnosis; Flow cytometry; Myelodysplastic syndromes

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD9 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN;

ANALYTIC METHOD; ANTIGEN EXPRESSION; B LYMPHOCYTE; CHROMOSOME ABERRATION; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; FLOW CYTOMETRY; GOLD STANDARD; HUMAN; INTERMETHOD COMPARISON; MYELOBLAST; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; FORECASTING; GRANULOCYTE PRECURSOR; METABOLISM; METHODOLOGY; PATTERN RECOGNITION; PRE B LYMPHOCYTE; REPRODUCIBILITY;

ANTIGENS, CD34; ANTIGENS, CD45; FLOW CYTOMETRY; FORECASTING; GRANULOCYTE PRECURSOR CELLS; HUMANS; MYELODYSPLASTIC SYNDROMES; PATTERN RECOGNITION, VISUAL; PRECURSOR CELLS, B-LYMPHOID; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 58949092332     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.857     Document Type: Review

References (51)

1. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
2. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
3. Yoshida Y, Stephenson J, Mufti GJ. Myelodysplastic syndromes: from morphology to molecular biology. Part I. Classification, natural history and cell biology of myelodysplasia. Int J Hematol 1993; 57: 87-97.
4. Ogata K. Myelodysplastic syndromes: recent progress in diagnosis and understanding of their pathophysiology. J. Nippon Med Sch 2006; 73: 300-307.
5. Mufti GJ, Galton DA. Myelodysplastic syndromes: natural history and features of prognostic importance. Clin Haematol 1986; 15: 953-971.
6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
7. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000; 24: 983-992.
8. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol 2001; 73: 405-410.
9. Hamblin TJ. Epidemiology of the myelodysplastic syndromes. In The Myelodysplastic Syndromes: Pathobiology and Clinical Management, Bennett JM (ed.). Marcel Dekker: New York, 2002; 15-27.
10. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007; 31: 727-736.
11. Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 2008; 32: 5-17.
12. Griffing GT, Melby JC. Enalapril (MK-421) and the white cell count and haematocrit. Lancet 1982; 1(8285): 1361.
13. Sica DA, Mannino R. Antihypertensive medications and anemia. J. Clin Hypertens (Greenwich) 2007; 9: 723-7727.
14. Hamblin T. Minimal diagnostic criteria for the myelodysplastic syndrome in clinical practice. Leuk Res 1992; 16: 3.
15. Kerndrup G, Bendix-Hansen K, Pedersen B, Ellegaard J, Hokland P. Analysis of leucocyte differentiation antigens in blood and bone marrow in patients with refractory anaemia (RA) and RA with sideroblasts. Prognostic implications of sequential and follow-up data. Eur J Haematol 1988; 41: 368-374.
16. Symeonidis A, Kourakli A, Katevas P, et al. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol 1991; 47: 277-281.
17. Colombat PH, Renoux M, Lamagnere JP, Renoux G. Immunologic indices in myelodysplastic syndromes. Cancer 1988; 61: 1075-1081.
18. Mittelman M, Karcher DS, Kammerman LA, Lessin LS. High Ia (HLA-DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes. Am J Hematol 199; 43: 165-171.
19. Hokland P, Kerndrup G, Griffin JD, Ellegaard J. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood 1986; 67: 898-902.
20. Kristensen JS, Hokland P. Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. Br J Haematol 1990; 74: 270-276.
21. Guyotat D, Campos L, Thomas X, et al. Myelodysplastic syndromes: a study of surface markers and in vitro growth patterns. Am J Hematol 1990; 34: 26-31.
22. Soligo DA, Oriani A, Annaloro C, et al. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. Am J Hematol 1994; 46: 9-17.
23. Oriani A, Annaloro C, Soligo D, Pozzoli E, Cortelezzi A, Lambertenghi Deliliers G. Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes. Br J Haematol 1996; 92: 360-364.
24. Elghetany MT. Surface marker abnormalities in myelodysplastic syndromes. Haematologica 1998; 83: 1104-1115.
25. Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98: 979-987.
26. Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394-403.
27. Kussick SJ, Wood BL. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med 2003; 127: 1140-1147.
28. Kussick SJ, Fromm JR, Rossini A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005; 124: 170-181.
29. Stachurski D, Smith BR, Pozdnyakova O, et al. Flow cytometric analysis of myelomonocytic cells by a pattern recognition approach is sensitive and specific in diagnosing myelodysplastic syndrome and related marrow diseases: emphasis on a global evaluation and recognition of diagnostic pitfalls. Leuk Res 2008; 32: 215-224.
30. Elghetany MT. Diagnostic utility of flow cytometric immuno-phenotyping in myelodysplastic syndrome. Blood 2002; 99: 391.
31. Cherian S, Moore J, Bantly A, et al. Peripheral blood MDS score: a new flow cytometric tool for the diagnosis of myelodysplastic syndromes. Cytometry B Clin Cytom 2005; 64: 9-917.
32. Malcovati L, Della Porta MG, Lunghi M, et al. Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia 2005; 19: 776-783.
33. Della Porta MG, Malcovati L, Invernizzi R, et al. Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia 2006; 20: 549-555.
34. Ogata K, Nakamura K, Yokose N, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 2002; 100: 3887-3896.
35. Ogata K, Yoshida Y. Clinical implications of blast immunophenotypes in myelodysplastic syndromes. Leuk Lymphoma 2005; 46: 1269-1274.
36. Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 2006; 108: 1037-1044.
37. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development. Blood 1987; 70: 1316-1324.
38. Loken MR, Wells DA. Normal antigen expression in hematopoiesis: basis for interpreting leukemia phenotypes. In Immunophenotyping, Stewart CC, Nicholson JKA (eds). Wiley-Liss: New York, 2000; 133-160.
39. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood 2001; 98: 2498-2507.
40. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005; 106: 2982-2991.
41. Oertel J, Kleiner S, Huhn D. Immunotyping of blasts in refractory anaemia with excess of blasts. Br J Haematol 1993; 84: 305-309.
42. Tien HF, Wang CH, Chuang SM, et al. Acute leukemic transformation of myelodysplastic syndrome - immunophenotypic, genotypic, and cytogenetic studies. Leuk Res 1995; 19: 595-603.
43. Longacre TA, Foucar K, Crago S, et al. Hematogones: a multi-parameter analysis of bone marrow precursor cells. Blood 1989; 73: 543-552.
44. Satoh C, Dan K, Yamashita T, Jo R, Tamura H, Ogata K. Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leuk Res 2008; 32: 699-707.
45. Nguyen D, Diamond LW, Braylan RC. FCM immunophenotyping and DNA analysis: practical aspects that can affect data analysis and interpretation. In Flow Cytometry in Hematopathology. Humana Press: New Jersey, 2003; 9-36.
46. Stewart CC, Stewart SJ. Cell preparation for the identification of leukocytes. In Flow Cytometry (2nd edn), Darzynkiewicz Z, Robinson JP, Crissman HA (eds). Academic Press: New York, 1994; 39-60.
47. Pirruccello SJ, Young KH, Aoun P. Myeloblast phenotypic changes in myelodysplasia. CD34 and CD117 expression abnormalities are common. Am J Clin Pathol 2006; 125: 884-894.
48. Wimazal F, Fonatsch C, Thalhammer R, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res 2007; 31: 1461-1468.
49. Paxton H, Bendele T. Effect of time, temperature, and anti-coagulant on flow cytometry and hematological values. Ann N Y Acad Sci 1993; 677: 440-443.
50. Stelzer GT, Marti G, Hurley A, McCoy P Jr, Lovett EJ, Schwartz A. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 1997; 30: 214-230.
51. Normann AP, Egeland T, Madshus IH, Heim S, Tjonnfjord GE. CD7 expression by CD34+ cells in CML patients, of prognostic significance? Eur J Haematol 2003; 71: 266-275.